| Literature DB >> 28395553 |
Athanasios Tsigaridas1, Ioannis S Papanikolaou2, Anna Vaiopoulou3, Athanasios K Anagnostopoulos4, Nikos Viazis1, George Karamanolis5, Dimitrios G Karamanolis1, George T Tsangaris4, Gerasimos J Mantzaris1, Maria Gazouli3.
Abstract
INTRODUCTION: Irritable bowel syndrome (IBS) is a gastrointestinal disease that according to Rome IV criteria is subdivided into four subtypes. The pathophysiology of this disease is not well understood due to numerous factors playing multiple roles in disease development, such as diet, stress and hormones. IBS has a variety of symptoms and overlaps with many other gastrointestinal and non-gastrointestinal diseases. Area covered: This review aims to present an overview of implementation of proteomics in experimental studies in the field of IBS. Expert commentary: Proteomics is commonly used for biomarker discovery in and has also been extensively used in IBS research. The necessity of a sensitive and specific biomarker for IBS is apparent, but despite the intensive research performed in this field, an appropriate biomarker is not yet available.Entities:
Keywords: Genetics; IBS; biomarkers; pathophysiology; proteomics
Mesh:
Substances:
Year: 2017 PMID: 28395553 DOI: 10.1080/14789450.2017.1317600
Source DB: PubMed Journal: Expert Rev Proteomics ISSN: 1478-9450 Impact factor: 3.940